Brief: Sanofi Terminates MOBILIZE Phase 3 Study Of Riliprubart In CIDP
10/06/2026 06:04
BRIEF-Sanofi Terminates MOBILIZE Phase 3 Study Of Riliprubart In CIDP June 10 (Reuters) - Sanofi SA SASY.PA:
TERMINATES RILIPRUBART MOBILIZE PHASE 3 STUDY IN CIDP PATIENTS REFRACTORY TO TREATMENT
CONTINUATION OF OTHER RILIPRUBART STUDIES INCLUDING VITALIZE PHASE 3 TO BE EVALUATED
TERMINATION OF MOBILIZE PHASE 3 STUDY WILL NOT IMPACT 2026 FINANCIAL GUIDANCE
NO SAFETY SIGNALS RELATED TO RILIPRUBART IDENTIFIED IN INTERIM ANALYSIS
DECISION FOLLOWS AN INTERIM ANALYSIS WHICH DETERMINED THAT MOBILIZE STUDY IS UNLIKELY TO PROVIDE SUFFICIENT EFFICACY
Source text: ID:nGNE2nnBsX
Further company coverage: SASY.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Sanofi SA
See all newsFDA approves expanded use of Sanofi's type 1 diabetes drug (updated)
Brief: FDA Approves Tzield For Pediatric Stage 3 Type I Diabetes
FDA approves Sanofi's drug for stage 3 type 1 diabetes in children
European shares steady as investors weigh US-Iran flare-up (updated)
European shares steady as investors cling to Mideast peace hopes